According to reports circulating last week, the Government is set to kick into the long grass the proposal for a national ...

Consultant urological surgeon Prof Nikhil Vasdev outlines what you should know about the second-most common cause of cancer ...

The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess ...

Dr. Khashayar Rafatzand is an Iranian-Canadian doctor in Montreal, who is changing the narrative when it comes to diagnosing ...

Learn more about prostate cancer and why there is a debate over whether or not patients should get tested for it.

By targeting a newly uncovered weakness in prostate cancer cells, this could offer an improved treatment for the disease.

Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients ...

THE march of AI now seems unstoppable in every part of our lives, from choosing the TV we watch to making our trains run on ...

As September concludes, the landscape of GU oncology continues to evolve, with important developments in prostate, bladder, ...

This early stage is often detected through routine screenings, such as a prostate-specific antigen (PSA) blood test and a digital rectal exam (DRE), before any symptoms arise. Because the disease is ...